DNAe, the next generation sequencing company developing novel diagnostics for use at the point-of-need, provides a business update on its LiDia-SEQ™ technology platform, and operational activities as the Company accelerates preparation of its commercialization strategy and roadmap.

DNAe, the next generation sequencing company developing novel diagnostics for use at the point-of-need, has expanded its Commercial team, appointing Supriya Mathur to the newly created role of Global Head of Communications.

DNAe co-founder Professor Christofer Toumazou has been officially announced as a laureate of the 2021 UNESCO-Equatorial Guinea International Prize for Research in the Life Sciences – the first UK winner.

Together with Imperial College London (‘Imperial’), DNAe has been awarded a UK Knowledge Transfer Partnership (KTP) by Innovate UK to support development of its next generation sequencing (NGS)-based diagnostic platform for use in cancer monitoring.

DNAe, the next generation sequencing company developing novel diagnostics for use at the point-of-need, today announces positive results from internal tests using its LiDia-SEQ™ sequencing technology to identify SARS-CoV-2. The SARS-CoV-2 coronavirus is the cause of the COVID-19 pandemic currently causing extensive mortality, morbidity and disruption globally.

DNAe, the next generation sequencing company developing novel diagnostics for use at the point-of-need, today announced that the US Food and Drug Administration (FDA) has granted it a “Breakthrough Device” designation for its pioneering platform and first assay.

DNAe, the next generation sequencing company developing novel diagnostics for use at the point-of-need, today provides an update on its response to the COVID-19 pandemic and announces that internal testing is underway to evaluate use of the LiDia-SEQ™ sequencing technology for the current SARS-CoV-2 pandemic and to help in containing future outbreaks.

DNAe, the next generation sequencing (NGS) company developing novel diagnostics for use at the point-of-need, provides an update on its significant research and development (R&D) and operational achievements in 2019.